To investigate the efficacy and safety of Bortezomib and Lenalidomide as induction, consolidation and maintenance therapy for untreated multiple myeloma patients eligible for autologous stem cell transplantation.

Trial Profile

To investigate the efficacy and safety of Bortezomib and Lenalidomide as induction, consolidation and maintenance therapy for untreated multiple myeloma patients eligible for autologous stem cell transplantation.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Antineoplastics; Cyclophosphamide; Dexamethasone; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms Kanshinetsu MMG001
  • Most Recent Events

    • 26 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 01 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top